Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $5.00

Karyopharm Therapeutics (NASDAQ:KPTI) had its target price raised by Piper Sandler from $4.00 to $5.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Friday, November 1st. StockNews.com upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Robert W. Baird dropped their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Price Performance

Shares of KPTI stock traded down $0.01 during trading hours on Wednesday, hitting $0.88. The stock had a trading volume of 980,812 shares, compared to its average volume of 844,336. The stock has a market capitalization of $109.88 million, a price-to-earnings ratio of -0.77 and a beta of 0.16. Karyopharm Therapeutics has a one year low of $0.62 and a one year high of $1.95. The stock’s 50-day moving average price is $0.81 and its two-hundred day moving average price is $0.91.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01. The company had revenue of $38.78 million during the quarter, compared to analysts’ expectations of $37.86 million. During the same quarter in the prior year, the business posted ($0.30) EPS. As a group, equities research analysts predict that Karyopharm Therapeutics will post -0.95 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Point72 DIFC Ltd bought a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $31,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $143,000. Acadian Asset Management LLC bought a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $167,000. Exchange Traded Concepts LLC raised its stake in shares of Karyopharm Therapeutics by 34.9% during the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after acquiring an additional 56,613 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $494,000. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).